Division of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California.
Division of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California.
JACC Cardiovasc Interv. 2018 Apr 9;11(7):648-661. doi: 10.1016/j.jcin.2017.11.034.
The aim of this study was to characterize post-procedural intravascular ultrasound (IVUS) findings in the ABSORB Japan trial, specifically stratified by the size of target coronary arteries.
Despite overall noninferiority confirmed in recent randomized trials comparing bioresorbable vascular scaffolds (BVS) (Absorb BVS) and cobalt-chromium everolimus-eluting metallic stents (CoCr-EES), higher event rates of Absorb BVS have been reported with suboptimal deployment, especially in small coronary arteries.
In the ABSORB Japan trial, 150 patients (2:1 randomization) were scheduled in the IVUS cohort. Small vessel was defined as mean reference lumen diameter <2.75 mm. Tapered-vessel lesions were defined as tapering index (proximal/distal reference lumen diameter) ≥1.2.
Overall, IVUS revealed that the Absorb BVS arm had smaller device expansion than the CoCr-EES arm did, which was particularly prominent in small- and tapered-vessel lesions. Higher tapering index was also associated with higher rates of incomplete strut apposition in Absorb BVS, but not in CoCr-EES. With respect to procedural techniques, small-vessel lesions were treated more frequently with noncompliant balloons at post-dilatation but using significantly lower pressure in the Absorb BVS arm. In contrast, tapered-vessel lesions were post-dilated at equivalent pressure but with significantly smaller balloon catheters in the Absorb BVS arm, compared with the CoCr-EES arm.
The significantly smaller device expansion especially in small vessels may account for the poorer outcomes of Absorb BVS in this lesion type. Appropriate optimization strategy, possibly different between polymeric and metallic devices, needs to be established for bioresorbable scaffold technology. (AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 Absorb™ BVS) in Japanese Population [ABSORB JAPAN]; NCT01844284).
本研究旨在对 ABSORB Japan 试验中的血管内超声(IVUS)术后结果进行特征描述,特别是根据目标冠状动脉的大小进行分层。
尽管最近的随机试验证实生物可吸收血管支架(BVS)(Absorb BVS)与钴铬依维莫司洗脱金属支架(CoCr-EES)相比具有非劣效性,但 Absorb BVS 的不良扩张率较高,尤其是在小冠状动脉中。
在 ABSORB Japan 试验中,150 例患者(2:1 随机分组)被纳入 IVUS 队列。小血管定义为平均参考管腔直径<2.75mm。锥形血管病变定义为锥形指数(近段/远段参考管腔直径)≥1.2。
总体而言,IVUS 显示 Absorb BVS 组的支架扩张小于 CoCr-EES 组,这在小血管和锥形血管病变中更为显著。较高的锥形指数也与 Absorb BVS 中不完全贴壁发生率较高相关,但在 CoCr-EES 中则不然。就介入技术而言,小血管病变在扩张后更频繁地使用顺应性球囊,但 Absorb BVS 组的压力显著较低。相比之下,锥形血管病变在扩张后压力相当,但 Absorb BVS 组的球囊导管明显较小,与 CoCr-EES 组相比。
尤其是在小血管中支架扩张明显较小,这可能是 Absorb BVS 在这种病变类型中结果较差的原因。需要为生物可吸收支架技术制定适当的优化策略,该策略可能在聚合物和金属装置之间有所不同。(AVJ-301 临床试验:日本人群中 AVJ-301 Absorb™ BVS 的临床评价[ABSORB JAPAN];NCT01844284)。